卡里奥制药公司（NASDAQ:KPTI）报告称，其季度每股亏损为$0.24，好于分析师一致预期的$0.26，超出7.69%。相比去年同期每股亏损$0.36，提升了33.33%。公司报告季度销售额为$3054万，低于分析师一致预期的$3486万，差距为12.40%。相比去年同期销售额$3375万，减少了9.50%。

以上内容来自Benzinga Earnings专栏，原文如下：

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.26) by 7.69 percent. This is a 33.33 percent increase over losses of $(0.36) per share from the same period last year. The company reported quarterly sales of $30.54 million which missed the analyst consensus estimate of $34.86 million by 12.40 percent. This is a 9.50 percent decrease over sales of $33.75 million the same period last year.